Wednesday, February 10, 2010, 2:03PM AEST - The Australian Stockmarket closes in 2 hours and 2 minutes.
To create a watchlist or portfolio of shares, Register

Cornerstone Therapeutics Inc. (CRTX)

8:00AM AEST: 5.01 USD  Up 0.05 (1.01%)  
 MORE ON CRTX 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Cornerstone Therapeutics Inc. (NCM:CRTX) Delayed quote dataEdit
Last Trade:5.01 USD
Trade Time: 8:00AM AEST
Change:Up 0.05 (1.01%)
Prev Close:4.96
Open:4.98
Bid:4.15 x 100
Ask:5.74 x 100
1y Target Est:13.00
Day's Range:4.90 - 5.06
52wk Range:2.73 - 12.29
Volume:26,063
Avg Vol (3m):49,877.8
Market Cap:125.82M
P/E (ttm):7.19
EPS (ttm):0.70
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add CRTX to Portfolio   Download Data

 HEADLINES 
Cornerstone Provides Guidance
Zacks.com (Tue, Jan 12)
Cornerstone Therapeutics gives 2010 forecasts
AP (Fri, Jan 8)
Cornerstone Therapeutics Provides 2010 Financial Guidance
PR Newswire (Thu, Jan 7)
7 Stocks Attracting Top Investors
at Motley Fool (Thu, Jan 7)
5 Top Stocks at Half Price
at Motley Fool (Wed, Dec 23)
Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
PR Newswire (Sat, Dec 19)
Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference
PR Newswire (Tue, Nov 24)
Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
PR Newswire (Sat, Nov 21)
Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference
PR Newswire (Tue, Nov 17)
CORNERSTONE THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Sat, Nov 14)
Cornerstone Therapeutics Appoints General Counsel
PR Newswire (Sat, Nov 14)
More Headlines for CRTX...

 ANALYST 
EPS Est (next year) (Dec-09) :0.34
EPS Est (in 2 years) (Dec-10) :0.01
Avg Rec (current)*:1.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Cornerstone Therapeutics Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for the respiratory market in the United States.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices